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A B S T R A C T
6-nitrobenzofuran-2-carbohydrazide Schiﬀ base derivatives have been synthesized and their structure has been
conﬁrmed via H1NMR, Mass spectrometry and elemental (CHN/S) analysis. These synthesized analogs showed
signiﬁcant cytotoxic and antioxidant activity. Doxorubicin (IC50 = 0.94± 0.20 μM) and n-propyl gallate (IC50
= 30.30± 0.40 μM) were used as standard in cytotoxic and antioxidant activities, respectively. Compound 1
(IC50 = 3.30±0.90 μM), 2 (IC50 = 2.70±0.25 μM), 3 (IC50 = 2.70± 0.25 μM), 10 (IC50 = 2.70±1.10 μM),
11 (IC50 = 1.00± 1.20 μM), and 17 (IC50 = 3.75± 0.90 μM) showed excellent while 21 (IC50 =
7.50±0.60 μM) and 28 (IC50 = 7.50± 0.66 μM) showed moderate anti cancer activity. Furthermore, com-
pound 10 (IC50 = 17.50±0.85 μM), 11 (IC50 = 24.20± 0.55 μM), 12 (IC50 = 21.10±1.58 μM), 13 (IC50 =
14.60±0.32 μM), 14 (IC50 = 29.20± 0.75 μM) and 15 (IC50 = 9.26± 0.15 μM) showed better antioxidant
activity than the standard n-propyl gallate. This study will be useful to develop potential lead molecules with
cytotoxic and antioxidant potential.
1. Introduction
Benzofuran containing heterocyclic constitutes one of the major
classes of organic compounds. Its presence is evidenced in several
bioactive natural products as well as pharmaceuticals and polymers
[19]. Numerous derivatives of benzofuran are known for their biolo-
gical and pharmacological relevancy [2,18,6]. This heterocyclic class of
compounds has attracted the tremendous attention of medicinal che-
mists who are actively involved in the synthesis of benzofuran ring
containing molecules and derivatives [7]. Several clinically approved
drugs based on benzofuran moiety which are either synthetic or natu-
rally found. There are many other substituted benzofuran derivatives
containing mono and fused benzofuran ring in conjunction with other
heterocyclic. Fig. 1 shows some of the drugs with their signiﬁcant
pharmacological activity.
Pyridylbenzofuran is known as antifungal, methoxsalen known for
treating eczema and psoriasis, and ﬂuorescein for its potential in di-
agnostics [8]. Further to this, pharmaceutically acceptable salts of
benzofuran class of compounds are inhibitors of leukotriene biosynth-
esis. These compounds inhibit the mammalian 5-lipoxygenase enzyme,
thus preventing the metabolism of arachidonic acid to the leukotrienes.
These compounds are thus useful in the treatment of asthma, allergic
disorders, inﬂammation, skin diseases and certain cardiovascular dis-
orders [1].
Many biological activities are associated with these classes of
compounds that include:
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